MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE
Albert Bourla, CEO of the pharmaceutical company Pfizer, arrives to ring the closing bell of the New York Stock Exchange.
Drew Angerer | Getty Images
Pfizer surpassed its top and bottom lines in the first quarter, driven by strong sales of Covid vaccine and oral antiviral drugs.
The pharmaceutical giant said it sold $ 13.2 billion in its Covid vaccine and $ 1.5 billion in antiviral drug Paxlovid in the first quarter.
Here’s how Pfizer performed compared to the expected Wall Street based on average analyst estimates compiled by Refinitiv:
- Customized EPS: $ 1.62 per share compared to an expected $ 1.47
- Revenue: $ 25.66 billion compared to an expected $ 23.86 billion
Pfizer shares were virtually unchanged in pre-sale trading.
The company has reaffirmed its plans for the full year 2022 on $ 32 billion in sales of Covid vaccine and $ 22 billion on Paxlovid.
This is a story in development. Check again for updates.
.
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE
Source